Henk Portengen

3.8k citations

40 papers · 3.1k indexed · h-index 29

Cancer Research top 1%
- Cancer, Hypoxia, and Metabolism 5
- Breast Cancer Treatment Studies 4
Oncology top 2%
- HER2/EGFR in Cancer Research 14
- Cancer-related Molecular Pathways 5
Immunology and Allergy top 2%
Genetics top 2%
- Estrogen and related hormone effects 13
Molecular Biology top 5%
Endocrinology, Diabetes and Metabolism
- Growth Hormone and Insulin-like Growth Factors 6
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 6
Epidemiology
- Neuroendocrine Tumor Research Advances 5

Co-authors: John A. Foekens Maxime P. Look Iris L. van Staveren Jan G.M. Klijn J.G.M. Klijn Wim L.J. van Putten Marion E. Meijer‐van Gelder J. Alexieva-Figusch
Cited by: Cancer Research Oncology Immunology and Allergy
Journals: Journal of Clinical Oncology (3 papers)JNCI Journal of the National Cancer Institute (1 paper)Cancer (1 paper)
Partner nations: Netherlands Germany Italy

In The Last Decade

Henk Portengen

40 papers receiving 3.0k citations

Peers

Countries citing papers authored by Henk Portengen

Since Specialization

Citations

This map shows the geographic impact of Henk Portengen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henk Portengen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henk Portengen more than expected).

Fields of papers citing papers by Henk Portengen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henk Portengen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henk Portengen. The network helps show where Henk Portengen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Henk Portengen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Henk Portengen Line = papers co-authored together Henk Portengen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	CHEK2 1100delC and male breast cancer in the Netherlands Breast Cancer Research and Treatment ·Marijke Wasielewski,Michael A. den Bakker,Ans van den Ouweland,Marion E. Meijer‐van Gelder,Henk Portengen,Jan G.M. Klijn,Hanne Meijers‐Heijboer,John A. Foekens,Mieke Schutte	2008	38
2	DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients Breast Cancer Research and Treatment ·Inko Nimmrich,Anieta M. Sieuwerts,Marion E. Meijer‐van Gelder,Ina Schwope,Joan Bolt‐de Vries,Nadia Harbeck,Thomas Koenig,Oliver Hartmann,Antje Kluth,Dimo Dietrich,Viktor Magdolen,Henk Portengen,Maxime P. Look,Jan G.M. Klijn,Ralf Lesche,Manfred Schmitt,Sabine Maier,John A. Foekens,John W.M. Martens	2007	85
3	Association of DNA Methylation of Phosphoserine Aminotransferase with Response to Endocrine Therapy in Patients with Recurrent Breast Cancer Cancer Research ·John W.M. Martens,Inko Nimmrich,Thomas Koenig,Maxime P. Look,Nadia Harbeck,Fabian Model,Antje Kluth,Joan Bolt‐de Vries,Anieta M. Sieuwerts,Henk Portengen,Marion E. Meijer‐van Gelder,Christian Piepenbrock,Alexander Olek,Heinz Höfler,Marion Kiechle,Jan G.M. Klijn,Manfred Schmitt,Sabine Maier,John A. Foekens	2005	102
4	How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study Clinical Cancer Research ·Anieta M. Sieuwerts,Marion E. Meijer‐van Gelder,Mieke Timmermans,Anita M.A.C. Trapman,Roberto Rodríguez García,Miranda Arnold,Anneke J.W. Goedheer,Henk Portengen,Jan G.M. Klijn,John A. Foekens	2005	71
5	Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling Journal of Clinical Oncology ·Maurice P.H.M. Jansen,John A. Foekens,Iris L. van Staveren,Maaike M. Dirkzwager-Kiel,Kirsten Ritstier,Maxime P. Look,Marion E. Meijer‐van Gelder,Anieta M. Sieuwerts,Henk Portengen,Lambert C. J. Dorssers,Jan G.M. Klijn,Els M.J.J. Berns	2005	264
6	Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features British Journal of Cancer ·E. Berns,Iris L. van Staveren,L.C. Verhoog,A M W van de Ouweland,M Meijer-van Gelder,Hanne Meijers‐Heijboer,Henk Portengen,John A. Foekens,Lambert C. J. Dorssers,J.G.M. Klijn	2001	12
7	p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. Journal of Clinical Oncology ·E. Berns,J.G.M. Klijn,W L van Putten,Hans H. de Witte,Maxime P. Look,Marion E. Meijer‐van Gelder,K. Willman,Henk Portengen,T J Benraad,John A. Foekens	1998	50
8	Expression of tumor‐associated 90k‐antigen in human breast cancer: No correlation with prognosis and response to first‐line therapy with tamoxifen International Journal of Cancer ·John A. Foekens,Jan G. M. Klun,Clara Natoli,Wim L.J. van Putten,P. Di Stefano,Maxime P. Look,Henk Portengen,Stefano lacobelli	1995	7
9	Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer JNCI Journal of the National Cancer Institute ·John A. Foekens,Maxime P. Look,Harry A. Peters,Wim L.J. van Putten,Henk Portengen,J.G.M. Klijn	1995	138
10	Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment Gene ·Els M.J.J. Berns,John A. Foekens,Iris L. van Staveren,Wim L.J. van Putten,Helen Y.W.C.M. de Koning,Henk Portengen,Jan G.M. Klijn	1995	143
11	Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer British Journal of Cancer ·JA Foekens,Henk Portengen,MP Look,WLJ van Putten,Benoı̂t Thirion,M. Bontenbal,J.G.M. Klijn	1994	47
12	The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study Breast Cancer Research and Treatment ·Jan G.M. Klijn,Maxime P. Look,Henk Portengen,J. Alexieva-Figusch,Wim L.J. van Putten,John A. Foekens	1994	101
13	Expression of epidermal growth factor receptor (EGFR) in non-affected and tumorous mammary tissue of female dogs Breast Cancer Research and Treatment ·Gerard R. Rutteman,John A. Foekens,Henk Portengen,J. H. Vos,Marinus A. Blankenstein,Erik Teske,Cees J. Cornelisse,W. Misdorp	1994	13
14	Prognostic factors in human primary breast cancer: Comparison of c-myc and HER2/neu amplification The Journal of Steroid Biochemistry and Molecular Biology ·E. Berns,John A. Foekens,Wim L.J. van Putten,Iris L. van Staveren,Henk Portengen,W. Köning,Jan G.M. Klijn	1992	41
15	Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: Correlation with steroid receptors European Journal of Cancer ·Els M.J.J. Berns,Jan G.M. Klijn,Iris L. van Staveren,Henk Portengen,Erica Noordegraaf,John A. Foekens	1992	97
16	Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects British Journal of Cancer ·J.G.M. Klijn,A.M. Hoff,A.S.T. Planting,Jaco J. Verweij,T.C. Kok,SWJ Lamberts,Henk Portengen,J.A. Foekens	1990	73
17	Treatment of breast cancer with different antiprogestins: Preclinical and clinical studies The Journal of Steroid Biochemistry and Molecular Biology ·G.H. Bakker,Buddy Setyono-Han,Henk Portengen,Frank H. de Jong,John A. Foekens,J.G.M. Klijn	1990	70
18	Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer Cancer ·John A. Foekens,Henk Portengen,Manon Janssen,Jan G. M. Klijn	1989	89
19	Comparison of enzyme immunoassay and dextran-coated charcoal techniques for progesterone receptor determination in human breast cancer cytosols Journal of Steroid Biochemistry ·John A. Foekens,Henk Portengen,Jolie van Driel,Wim L.J. van Putten,W. G. Haije,Jan G.M. Klijn	1988	3
20	Treatment of patients (PTS) with metastatic pancreatic and gastrointestinal tumors with a somatostatin analog (sandostatin): A phase II study including endocrine effects Journal of Steroid Biochemistry ·J.G.M. Klijn,A.M. Hoff,J. Verwelj,André Planting,Henk Portengen,Steven W. J. Lamberts,John A. Foekens	1987	1

About Henk Portengen

Henk Portengen is a scholar working on Cancer Research, Oncology and Genetics, having authored 40 papers that have together received 3.1k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (14 papers), Estrogen and related hormone effects (13 papers), Growth Hormone and Insulin-like Growth Factors (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Neuroendocrine Tumor Research Advances (5 papers), Cancer, Hypoxia, and Metabolism (5 papers), Cancer-related Molecular Pathways (5 papers) and Breast Cancer Treatment Studies (4 papers). The work is most often cited by research in Cancer Research (1.2k citations), Oncology (1.5k citations) and Immunology and Allergy (249 citations). Henk Portengen has collaborated with scholars based in Netherlands, Germany and Italy. Frequent co-authors include John A. Foekens, Maxime P. Look, Iris L. van Staveren, Jan G.M. Klijn, J.G.M. Klijn, Wim L.J. van Putten, Marion E. Meijer‐van Gelder, J. Alexieva-Figusch, W L van Putten and Harry A. Peters. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact